[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","fguhdcl5e36xw31ds0l006iu1","revision",2,"title","TScan Therapeutics, Inc. 董事变动公告","originalTitle","TScan Therapeutics, Inc. (0001783328) (Filer)","summary","TScan Therapeutics, Inc. 董事 Garry Nicholson 和 Gabriela Gruia 医师于 2026 年 10 月 13 日辞职。公司同时任命 Stephen Biggar 和 R. Keith Woods 接替相关委员会职务。公告未提及辞职原因。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-10-16T20:45:13.000Z","discoveredAt","2026-10-16T22:50:16.091Z","timelineAt","category","tip","tags",[81,82,83],"stockSymbols",[80],"score",30,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","flGpMoemuQAI",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","9d7b7eef-f411-4c2c-b855-c217adbdc756","TScan Therapeutics 董事变动",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 13, 2026

TSCAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

\n\n\n\n\n\n\n\n\n\n\n\n\n\n

Delaware

001-40603

82-5282075

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	\n
830 Winter Street
Waltham, Massachusetts		02451
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 857 399-9500

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

\n\n\n

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

\n\n\n

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

\n\n\n

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

\n\n\n

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Voting Common Stock, par value $0.0001 per share

TCRX

The Nasdaq Global Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

\n\n\n

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Garry Nicholson and Gabriela Gruia, M.D.

On October 13, 2026, each of Garry Nicholson and Gabriela Gruia, M.D., resigned from the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) and each committee thereof, in each case effective as of October 13, 2026 (the “Resignations”). Neither Mr. Nicholson’s nor Dr. Gruia’s resignation was a result of any disagreement with the Company on any matter relating to the Company’s operations, practices or policies. In connection with the Resignations, the Board appointed Stephen Biggar and R. Keith Woods to the Nominating and Corporate Governance Committee (the “NCG Committee”) as member and chairperson, respectively, effective as of October 13, 2026. The NCG Committee now consists of R. Keith Woods, Katina Dorton and Stephen Biggar. The Audit Committee now consists of Katina Dorton, Barbara Klencke and R. Keith Woods.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n\n	\n	\n\n	\n	\n\n	\n
\n		\n		\n		TScan Therapeutics, Inc.
\n	\n	\n
Date: October 16, 2026		\n		By:		/s/ Gavin MacBeath, Ph.D.
\n		\n		\n		Gavin MacBeath, Ph.D. Chief Executive Officer (Principal Executive Officer)

","zhKind","complete","TCRX","政策与监管","退市","停复牌","aihot","/items/fguhdcl5e36xw31ds0l006iu1","https://www.sec.gov/Archives/edgar/data/1783328/000119312526424198/0001193125-26-424198-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792454400&sig=3dbe6cd67490ee5b","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792454400&sig=28d09d2ec91c5a63 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792454400&sig=4324ec5a457d0f39 96w","changelogVersion","2026-10-01T08:00"]